Kornimate/medical-research-clean huggingface dataset:
is optimal minute ventilation a predictor of weaning in patients with prolong mechanical ventilation?

Conditions: Chronic Respiratory Failure

Summary: 1. purpose of study: optimal minute could be the prediction of successful weaning and become the new weaning parameter. 2. study design: inclusion criteria: investigators will perform this study at our respiratory care center. patients who had been maintained on mechanical ventilator in excess of 3 weeks before respiratory care center admission and all previous weaning attempts had ailed. exclusion criteria: patients do not have spontaneous breath. terminal cancer stage and unstable hemodynamics condition. 3. study duration: 2016/01/01\~12/31

investigators will preform this study at our respiratory care center. initially, investigators collected all physiological parameters and baseline characteristics of patients with prolong mechanical ventilator. investigators use gold-galileo ventilator and patients use adaptive support ventilation mode. in adaptive support ventilation, the clinician enters a target minute volume , using a parameter called minute ventilation percentage. the minute ventilation percentage setting be initially set at 100% (the 100%minute ventilation setting), which provides a target minute ventilation of 0.1 l/min/kg of ideal body weight . investigators observed respiratory frequency of patients, the minute ventilation percentage was increased every 5 min until the mandatory breath began to appear and spontaneous rate is zero. if the minute ventilation percentage had exceeded 250%, but patients do not have mandatory rate appeared, the optimal minute ventilation of the patient is means above 250%. investigators also measure other weaning parameters. finally, investigators analyze the prediction of optimal minute ventilation as a weaning parameter.

Eligibility criteria:
inclusion criteria: * patients who had been maintained on mechanical ventilation in excess of 3 weeks before respiratory care center admission and all previous weaning attempts had failed. exclusion criteria: * patients do not have spontaneous breath. patients do not use invasive mechanical ventilator. terminal cancer stage and hemodynamics unstable.
unsupported upper extremity exercise test in chronic neck pain

Conditions: Neck Pain; Upper Extremity Dysfunction

Summary: the aim of this study was to examine the validity and test-retest reliability of unsupported upper extremity exercise test (uulex) in individuals with chronic neck pain. patients with neck pain lasting at least 3 months will be included in the study. it is planned to examine the validity and test-retest reliability of the uulex test in that patient groups.

persons with chronic neck pain may limit the functional use of their upper extremities. it is recommended to determine appropriate upper extremity measurement methods in patients with chronic neck pain. therefore the aim of this study was to examine the validity and test-retest reliability of unsupported upper extremity exercise test (uulex) in individuals with chronic neck pain. six minute pegboard ring test, 30-second push-up test and arm, shoulder and hand injury questionnaire (dash), visual analog scale, neck disability index, new york posture rating chart and short form-36 health survey were used to evaluate the validity of the test. for test-retest reliability, the unsupported upper extremity test was repeated 1 week later by the same investigator.

Eligibility criteria:
inclusion criteria: * 18-65 years old exclusion criteria: * presence of additional disease affecting upper extremity and hand functions (carpal tunnel syndrome, trigger finger, impingement syndrome,thoracic outlet syndrome, lateral and medial epicondylitis, hand osteoarthritis, etc.), * having undergone upper extremity or cervical region surgery * cervical radiculopathy, rheumatic disease, presence of neurological symptoms * according to the visual analogue scale (vas), neck pain intensity in activity is less than 3, * acute or chronic respiratory illness * cardiac disease * problem recognizing verbal commands * pregnancy

Keywords: chronic neck pain upper extremity test validity reliability
a long-term follow-up study of multiple sclerosis patients who participated in genzyme-sponsored studies of gz402668

Conditions: Progressive Multiple Sclerosis

Summary: primary objective: to assess the long-term safety of gz402668 in patients with multiple sclerosis (ms) who received prior treatment during the tdu13475 or tdu14981 studies. secondary objectives: to assess the pharmacokinetics of gz402668 in patients with ms. to assess the pharmacodynamics of gz402668 in patients with ms. to assess the immunogenicity of gz402668 in patients with ms.

the total study duration for a patient is approximately 47 months. there is no administration of gz402668 in the lts14120 study. patients who already received investigational medicinal product (gz402668 or placebo) in tdu13475 or tdu14981 will be followed up to 47 months in the lts14120. note: patients from tdu14981 study (sanofi-sponsored) will participate in lts14120 study. in order to keep consistent among all study related documents, the title of the lts14120 study is not amended.

Eligibility criteria:
inclusion criteria: received investigational medicinal product (gz402668 or placebo) in tdu13475 or tdu14981 the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
study of hyperkyphosis, exercise and function-sheaf

Conditions: Kyphosis

Summary: we propose to conduct a randomized, controlled trial among 100 men and women aged 60 or older with hyperkyphosis to an exercise intervention that includes kyphosis-specific spinal muscle strengthening exercises compared to a usual care control group. the study will be conducted in five waves,with 10 participants in the exercise intervention and 10 participants in the control group in each wave.

the experimental interventions will be provided in small groups meeting three sessions per week for 6 months. at baseline and 6 months after the intervention, we will measure kyphosis, physical function, spine muscle strength and density, and quality of life. we will assess the effect of the intervention on the co-primary outcomes of kyphosis, modified physical performance test (ppt) and gait speed measured as change over 6 months. we will also assess the effect of the intervention on secondary outcomes of physical function and health-related quality of life, measured as change in timed up and go, timed loaded standing, six-minute timed walk, the scoliosis research society srs-30, promise global health and physical function and pace questionnaires. furthermore, we will investigate whether changes in kyphosis, spinal muscle strength and/or density mediate the effect of the intervention on change in physical function. after the 6-month intervention, both groups will continue their usual activity and we will assess the durability of the effects of the intervention at 1-year follow-up.

Eligibility criteria:
inclusion criteria: * age 60 years and older, kyphosis angle \>= 40 degrees measured by kyphometer, medical approval from study physician and primary care provider to participate in exercise intervention exclusion criteria: * gait speed \<0.6 meters/sec, inability to rise from a chair with arms crossed at chest, painful vertebral fractures in the past 3 months, 3 or more falls in the past year, advanced disability or end-stage disease, major psychiatric illness, cognitive impairment, alcohol, drug abuse, or narcotic pain medications, uncontrolled hypertension, peripheral neuropathy associated with type i diabetes, chest pain, myocardial infarction, or cardiac surgery within the previous 6 months, diagnosed vestibular or neurologic disorder, total hip or knee replacement or hip fracture within previous 6 months, oral glucocorticoid medications for ≥ 3 months the past year, no active movement in thoracic spine, unable to execute exercise safety tests, failure to comply with run-in procedures: poor attendance, or use of actigraph, non-english speaking

Keywords: kyphosis
the effectiveness of nasal corticosteroids versus placebo in nasal obstruction in patients with nasal septal deviation

Conditions: Nasal Obstruction

Summary: the purpose of this project is to determine if intranasal corticosteroids have an effect on nasal obstruction in patients with nasal septal deviation.

participants were identified at their initial visit to the stanford facial plastic and reconstructive surgery clinic, an academic referral center, in consultation for nasal obstruction. if eligible and interested in participating, patients provided written informed consent prior to randomization. eligible participants were patients over the age of 18 years of age with the presence of nasal septal deviation as identified by physical examination, as well as a baseline nose score of 35 or greater. exclusion criteria included a history of nasal or septal surgery, use of intranasal steroids in the three months preceding enrollment, use of systemic steroids in the six months preceding enrollment, and pregnancy or active breastfeeding at the time of enrollment. in order to maximize generalizability of the study, no medications other than systemic and intranasal steroids were used as exclusion criteria. all study participants received 6 weeks of therapy with an intranasal steroid spray, nasacort (chattem inc), which consists of the steroid triamcinolone acetonide, as well as 6 weeks of placebo with ayr saline spray (b.f. ascher). these two study drugs were packaged identically by a local pharmacist and labelled drug a and drug b. nasacort was selected as the intranasal steroid following pharmacist consultation, as this intranasal steroid is less scented than others and therefore was less likely to be distinguishable from the placebo to participants. participants were instructed to use both drugs as follows: 1 spray per nostril twice a day. researchers, statistical analysts, and study participants were blinded to the identity of the two drugs until the conclusion of the study. a duration of 6 weeks per drug was selected based on the most commonly observed insurance requirements seen in our practice. following unblinding, it was determined that drug a was the placebo, the saline spray, and drug b was the test drug, the nasal steroid. following completion of both study drugs, patients were offered surgical intervention. if interested and medically cleared for surgery, patients underwent surgery. all surgeries were performed by the senior author and included open septorhinoplasty to address septal deviation, with repair of nasal valve stenosis and inferior turbinate reduction performed in some patients as deemed necessary by the senior author.

Eligibility criteria:
inclusion criteria: * age greater than 18 * nose score greater than 55 * nasal septal deviation on exam exclusion criteria: * intranasal steroid use within the last three months * current systemic steroid use * prior septal surgery * individuals who are pregnant or actively breastfeeding
the effects of dry needling on patients with knee pain

Conditions: Patellofemoral Pain Syndrome; Anterior Knee Pain Syndrome

Summary: this study is testing the effectiveness of "dry needling" for pain management and on muscle strength and leg function for those with knee pain. dry needling consists of small, monofilament needles that are administered directly into the tissue and manipulated to make the muscle relax for pain relief. this technique is used to treat dysfunctions in skeletal muscle and connective tissue to help diminish pain, reduce impairments of body structure and restore function.

this project will evaluate the effects of dry needling on pain, muscle performance, and function in those with patellofemoral pain syndrome (pfps) of the knee. variables of interest will include self-reported pain scores, self-reported functional outcome and disability questionnaire scores, and various objective clinical measures including muscle strength, joint range of motion, and movement patterns during basic tasks related to activities of daily living. patients who are referred to physical therapy with pfps will be recruited. patients will be randomly and equally allocated into one of the following groups: 1. gluteal dry needling (glute) 2. quadriceps dry needling (quad) 3. sham gluteal dry needling (sham glute) 4. sham quadriceps dry needling (sham quad) 5. control group (control) groups 1-4 will receive 2 sessions of dry needling or sham dry needling to the gluteal and/or quadricpes muscles on their painful lower limb over 2 consecutive weeks in addition to standard physical therapy. the control group will only receive standard physical therapy. the sham treatment groups (groups 3-4) will receive a placebo treatment that does not penetrate the skin or muscles. measurements will be performed at baseline prior to any physical therapy interventions and then at week 3.

Eligibility criteria:
inclusion criteria: * 18-40 years-of-age * referred for physical therapy * presence of anterior knee pain around the patella during ascending/descending stairs, squatting, and/or running for at least 3 months. exclusion criteria: * unable to provide consent * bilateral patellofemoral pain syndrome * received previous dry needling treatments * pregnancy * history of pain less than 3 months * imaging demonstrating the presence of confounding internal abnormality (e.g. chondral defects, ligamentous injury, and/or meniscal pathology), * patellar instability * presence of a neurological condition that would affect movement * contraindications to dry needling techniques (e.g. a history of bleeding disorders, phobia of needles, an active cancer diagnosis, and presence of other systemic illness such as fever or signs of infection) * actively receiving treatment for knee pain outside of the current study protocol while enrolled in the study; * received active and supervised pt treatment for knee pain within the last 4 weeks; * history of knee surgery less than 6 months ago * history of surgical correction of the patellofemoral complex (e.g. mpfl reconstruction, patellar realignment surgery, etc)
intraoperative blood pressure and cognitive performance

Conditions: Cognitive Performance; Hypertension

Summary: the purpose of this study is to prospectively determine the association between incidence of neurological morbidity and minimum fractional blood pressure reached during laminectomy procedures under general anesthesia in hypertensive and normotensive subjects 40 years old and older.


Eligibility criteria:
inclusion criteria: * english as first language, or as a learned language as long as the patient is proficient * no history of any neurological disease with the exception of patients without functional impairment who suffered a single episode of transient ischemic attack * no history of axis i psychiatric diagnosis or drug abuse * 40 years old or older * undergoing laminectomy under general anesthesia * must not take antihypertensive medication for purposes other than treatment of hypertension exclusion criteria: * anyone who do not fit the inclusion criteria.
open label study assessing effectiveness of amlodipine/atorvastatin in subjects with hypertension and dyslipidaemia

Conditions: Hypertension; Dyslipidemia

Summary: to evaluate the effectiveness of amlodipine/atorvastatin therapy by assessing the percentage of subjects who reach target blood pressure (bp) and ldl-c targets as defined by their governing guidelines.


Eligibility criteria:
inclusion criteria: * patients who are above target ldl-c and bp who are eligible for treatment exclusion criteria: * high liver enzymes
intraoperative pain after infiltration technique using artpharma versus artinibsa in children

Conditions: Pain, Postoperative

Summary: the aim of this study is to assess intraoperative pain for extraction of maxillary primary molars using artpharma versus artinibsa in children during infiltration technique.

articaine is used for pain control like other local anesthetic drugs, articaine causes a temporary and completely reversible state of anesthesia (loss of sensation) during (dental) procedures.this local anesthesia was first synthesized by rusching in 1969, and carried to the market in germany by hoechst ag, a life-sciences german company, under the brand name ultracain ,it entered clinical practice in germany in 1976. the name was changed in 1984, the year it was released in canada. it then entered the united kingdom in 1998, the united states in 2000 and australia in 2005. at this time, articaine is available as a 4% solution containing 1:100, 000 or 1:200, 000 adrenaline. articaine has been widely used in dental surgery.it started to use carticaine around 1977.in dentistry has been investigated widely. articaine is a unique amide la in that it contains a thiophene, instead of a benzene ring.the thiophene ring allows greater lipid solubility and effectiveness as a greater portion of an administered dose can enter neurons

Eligibility criteria:
inclusion criteria: * children aged 6-9 years. * children with maxillary primary molars indicated for extraction. exclusion criteria: * children with medical conditions. * uncooperative children. * parents or guardians who refuse participating in the study.

Keywords: articaine extraction primary teeth infiltration technique postoperative pain intraoperative pain
pain of patients, suffering of caregivers: evaluation of the benefit of full consciousness meditation in oncology

Conditions: Cancer; Pain

Summary: the study is based on the realization of a meditation program associating patients, caregivers and control subjects


Eligibility criteria:
inclusion criteria for all participants (patients, caregivers and control subjects) * participants aged 18 or over * curious and motivated participant to participate in the program * participant with no current or previous experience of regular or intensive practice of meditation or a comparable practice. the practice is considered regular and / or intensive if: * it occurs more than one day per week for more than 6 consecutive months over the last 10 years, * and / or in case of more than 5 consecutive days of intensive practice (internship or retirement) in the last 10 years, * and / or more than 25 consecutive days of (cumulative) retirement over the last 10 years. * participant available to follow the full meditation program (3 month period) * participant agreeing to participate by signing the study information note * participant able to understand, speak and read french * patient capable of using digital media and having an internet connection patient-specific criteria (target population) * patients with cancer, * state of health compatible with the study meditation program * patient affiliated to a social health sytem caregiver-specific criteria * all medical and / or paramedical staff of the sponsor center in contact with patients (doctors, nurse, caregiver, radiotherapy manipulator merm) criteria specific to the control population - any voluntary person not belonging to the two categories above exclusion criteria: for all participants * participant with significant vulnerability factors dependence on alcohol and drugs, severe depression, severe social anxiety, recent mourning etc.). * participant who cannot submit to the follow-up of the trial for geographic, social or psychopathological reasons for patients * very advanced stage of cancer disease with life-threatening commitment, * participant deprived of liberty or under guardianship for control subjects - nursing staff, regardless of their place of practice

Keywords: meditation caregivers patients with cancer
multinational clinical study comparing isatuximab, carfilzomib and dexamethasone to carfilzomib and dexamethasone in relapse and/or refractory multiple myeloma patients

Conditions: Plasma Cell Myeloma

Summary: the purpose of this study it to compare the efficacity of isatuximab when combined to carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with multiple myeloma already treated with 1 to 3 prior lines of therapy.

the duration of the study for a patient will include a period for screening of up to 3 weeks. patients will be treated until disease progression, unacceptable ae, or patient decision to stop the study treatment. after study treatment discontinuation, patients will have follow-up visits until the analysis of overall survival.

Eligibility criteria:
inclusion criteria: * participants with mm previously treated with prior 1 to 3 lines and with measurable serum m-protein (\>= 0.5 gram/deciliter) and/or urine m-protein (\>= 200 milligram/24 hours). exclusion criteria: * participants previously pretreated with carfilzomib, who never achieved at least one minor response during previous therapies and/or last previous therapy completed within 14 last days. * participants with serum free light chain (flc) measurable disease only. * participants less than 18 years old, participants with eastern cooperative oncology group performance status more than 2. * participants with inadequate biological tests. * participants with myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, new york heart association class iii or iv congestive heart failure, superior or equal to grade 3 arrhythmias, stroke or transient ischemic attack within last 6 months, and/or left ventricular ejection fraction lower than 40%. * participants with previous cancer unless disease free for more than 5 years or in situ cancer curatively treated. * participants with known acquired immunodeficiency syndrome related illness or human immunodeficiency virus requiring antiretroviral treatment, or hepatitis a, b, or c active infection. * women of childbearing potential or male participant with women of childbearing potential who do not agree to use highly effective method of birth control. the above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Keywords: anti-cd38 monoclonal antibody
feasibility of doctors' rooms-based infusion of zoledronic acid

Conditions: Osteoporosis

Summary: 1. the study will assess the safety and tolerability of a single-infusion of zoledronic acid 5 mg administered in a private medical practice setting by a nurse provided by a nationwide infusion service. safety data will largely be monitored by investigating changes in the patients' well-being during the study. 2. the study will pilot and test a patient registry and infusion service process, which will allow zoledronic acid to be administered to trial patients in the investigators' private rooms by a team of roving nurses.


Eligibility criteria:
inclusion criteria: 1. female after menopause with osteoporosis either: 70 years of age or older with a bone mineral density t-score of -3.0 or less or with a fracture due to minimal trauma. exclusion criteria: 1. intravenous bisphosphonate within the past 12 months 2. abnormal levels of protein in the urine via dipstick at screening if not caused by bacterial infection 3. abnormal liver function tests greater than twice normal 4. evidence of high bone turnover 5. abnormal calcium blood levels 6. low vitamin d levels 7. poor renal function 8. abnormal parathyroid function or uncontrolled, abnormal thyroid function 9. history of eye inflammation 10. history of diabetes leading to kidney or eye problems 11. a history of cancer except some non-invasive cancers of skin, colon, breast and cervix 12. patients with severe dental problems or current dental infections or requiring dental surgery 13. known sensitivity to zoledronic acid or bisphosphonates other protocol defined inclusion/exclusion criteria may apply

Keywords: osteoporosis zoledronic acid postmenopausal women